CRISPR Editing of Msh3 Gene Reduces Huntington's Disease Progression in Mice
Researchers used CRISPR-Cas9 to knock out the Msh3 gene in mice with Huntington's disease, finding that the intervention slowed CAG repeat expansion and reduced disease pathology at multiple treatment timepoints. Huntington's disease is caused by CAG repeat expansion in the HTT gene, and somatic expansion in neurons drives disease onset; MSH3 is a protein that promotes this expansion. The findings suggest that targeting MSH3 could be a disease-modifying therapeutic strategy, with earlier intervention showing greater benefit.
In a preclinical study published on bioRxiv, researchers demonstrated that somatic CRISPR-Cas9 editing targeting the Msh3 gene mitigated Huntington's disease pathology in transgenic mice. The team treated HttQ111 mice at three different ages (6, 16, and 24 weeks) representing progressively advanced disease stages. Across all treatment timepoints, Msh3 knockout slowed striatal CAG repeat expansion, reduced nuclear huntingtin protein pathology, and suppressed transcriptional dysregulation associated with the disease. Earlier intervention produced greater therapeutic impact than later treatment. The intervention also suppressed production of the exon 1 Htt1a transcript variant. These results provide preclinical evidence supporting MSH3 as a therapeutic target in humans, though the authors note that such therapies would likely impact only a subset of brain cells.
What's missing
The study does not discuss potential off-target effects of CRISPR editing, long-term durability of the therapeutic effect, or how findings in mice might translate to human efficacy and safety. The authors do not address whether this approach could be combined with other therapeutic strategies or how it might interact with existing Huntington's disease treatments.
What different sources said
- bioRxivCenter
Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice
Related
Study Shows Statins Reduce Coenzyme Q in Brain Cells, Impairing Mitochondrial Function
A laboratory study found that statin drugs decrease coenzyme Q levels in astrocytes (brain support cells) by 30-40%, reducing their mitochondrial energy production and increasing oxidative stress. Astrocytes are critical for maintaining brain health and protecting neurons from damage. The findings suggest CoQ10 supplementation may help counteract these effects, though human clinical evidence remains limited.
Study reveals zebrafish larvae exhibit slowly fluctuating directional swim biases driven by internal dynamics
Researchers found that 5-day-old zebrafish larvae display changing directional swim preferences over many hours even in stable environments, contrary to classical models assuming constant individual biases. Computational analysis suggests these fluctuations arise from a non-stationary Markovian process with two independent internal input streams modulating swim direction repetition. The findings suggest animals possess intrinsic mechanisms for generating behavioral variability independent of external stimuli, with implications for understanding how internal states shape adaptive behavior.
Two Small Molecules Show Promise as Broad-Spectrum Coronavirus Inhibitors in Laboratory Study
Researchers found that sennoside A and ceftazidime, two small molecules, can inhibit RNA binding in the nucleocapsid proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV in laboratory experiments. The nucleocapsid protein is highly conserved across coronaviruses and essential for viral replication, making it a potential drug target. The findings suggest these compounds could form the basis for pan-coronavirus antiviral therapies, though further development and clinical testing would be needed.